Controlling protein interactions in blood for effective liver immunosuppressive therapy by silica nanocapsules.
Animals
Cell Survival
Colloids
Cytokines
/ metabolism
Dexamethasone
/ administration & dosage
Drug Delivery Systems
Drug Stability
HeLa Cells
Humans
Immunosuppression Therapy
/ methods
Immunosuppressive Agents
/ administration & dosage
Liver
/ cytology
Mice
Nanocapsules
/ administration & dosage
Silicon Dioxide
/ administration & dosage
Tissue Distribution
Journal
Nanoscale
ISSN: 2040-3372
Titre abrégé: Nanoscale
Pays: England
ID NLM: 101525249
Informations de publication
Date de publication:
28 Jan 2020
28 Jan 2020
Historique:
pubmed:
16
1
2020
medline:
21
10
2020
entrez:
16
1
2020
Statut:
ppublish
Résumé
Immunosuppression with glucocorticoids is a common treatment for autoimmune liver diseases and after liver transplant, which is however associated with severe side-effects. Targeted delivery of glucocorticoids to inflammatory cells, e.g. liver macrophages and Kupffer cells, is a promising approach for minimizing side effects. Herein, we prepare core-shell silica nanocapsules (SiO
Substances chimiques
Colloids
0
Cytokines
0
Immunosuppressive Agents
0
Nanocapsules
0
Silicon Dioxide
7631-86-9
Dexamethasone
7S5I7G3JQL
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM